These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
521 related articles for article (PubMed ID: 27097592)
1. Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications. Dowlat HA; Kuhlmann MK; Khatami H; Ampudia-Blasco FJ Diabetes Obes Metab; 2016 Aug; 18(8):737-46. PubMed ID: 27097592 [TBL] [Abstract][Full Text] [Related]
2. [Biosimilars in oncology: a therapeutic alternative to the reference products?]. Ludwig WD; Dicheva S Z Gastroenterol; 2016 Nov; 54(11):1223-1229. PubMed ID: 27723912 [TBL] [Abstract][Full Text] [Related]
3. Regulation of biosimilar medicines and current perspectives on interchangeability and policy. O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103 [TBL] [Abstract][Full Text] [Related]
4. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable. Afzali A; Furtner D; Melsheimer R; Molloy PJ Adv Ther; 2021 May; 38(5):2077-2093. PubMed ID: 33745111 [TBL] [Abstract][Full Text] [Related]
5. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876 [TBL] [Abstract][Full Text] [Related]
6. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832 [TBL] [Abstract][Full Text] [Related]
7. Biosimilar medical products - licensing, pharmacovigilance and interchangeability. Grozdanova A; Netkovska KA; Sterjev Z; Naumovska Z; Zarevski R; Dimovski A; Suturkova L Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016; 37(1):27-36. PubMed ID: 27442414 [TBL] [Abstract][Full Text] [Related]
8. Biosimilars: A consideration of the regulations in the United States and European union. Daller J Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800 [TBL] [Abstract][Full Text] [Related]
10. The biosimilar insulin landscape: current developments. Lavalle-González FJ; Khatami H Postgrad Med; 2014 Oct; 126(6):81-92. PubMed ID: 25414937 [TBL] [Abstract][Full Text] [Related]
11. From bioequivalence to biosimilars: How much do regulators dare? Weise M Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000 [TBL] [Abstract][Full Text] [Related]
12. The advent of biosimilars for the treatment of diabetes: current status and future directions. Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669 [TBL] [Abstract][Full Text] [Related]
14. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors]. Jahnz-Rozyk K; Wiesik-Szewczyk E; Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192 [TBL] [Abstract][Full Text] [Related]
15. A Comprehensive Overview on Biosimilars. Kadam V; Bagde S; Karpe M; Kadam V Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165 [TBL] [Abstract][Full Text] [Related]
16. Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence. Trifirò G; Marcianò I; Ingrasciotta Y Expert Opin Biol Ther; 2018 Mar; 18(3):309-315. PubMed ID: 29186988 [TBL] [Abstract][Full Text] [Related]
17. The Regulation of Biosimilars in Latin America. Garcia R; Araujo DV Curr Rheumatol Rep; 2016 Mar; 18(3):16. PubMed ID: 26951254 [TBL] [Abstract][Full Text] [Related]
18. Are we ready to close the discussion on the interchangeability of biosimilars? Ebbers HC; Schellekens H Drug Discov Today; 2019 Oct; 24(10):1963-1967. PubMed ID: 31254488 [TBL] [Abstract][Full Text] [Related]
19. [Biosimilars, no generic biologicals!]. Knuts B J Pharm Belg; 2016 Dec; (4):24-29. PubMed ID: 30281245 [TBL] [Abstract][Full Text] [Related]
20. Biosimilar medicines - Review. Dos Reis C; Teixo R; Mendes F; Cruz RS Int J Risk Saf Med; 2016 Mar; 28(1):45-60. PubMed ID: 27176756 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]